What is driving growth in the Turkey pharmaceutical market?
The Turkey pharmaceutical market is expanding steadily on the back of government-led initiatives to strengthen local drug manufacturing, increased investment in R&D, growing demand for biologics and generics, and improved access to healthcare. In 2024, the market was valued at USD 10.12 billion and is projected to reach USD 14.98 billion by 2034, growing at a CAGR of 4.00%. The market growth is supported by the government’s Strategic Action Plans for the Pharmaceutical Industry, which encourage local production, boost biosimilar adoption, and enhance international competitiveness of Turkey’s pharma exports. Rising healthcare expenditures, expanding insurance coverage, and evolving patient needs for chronic disease management are also key market drivers.
What is the current status of the Turkey pharmaceutical market and why is it growing?
The Turkey pharmaceutical market includes the production, distribution, and sales of both innovative and generic drugs, biosimilars, vaccines, and emerging therapies. Turkey is positioning itself as a regional hub for pharmaceutical innovation due to cost-competitive manufacturing, skilled healthcare professionals, and government support.
The market is growing because:
-
Government incentives supporting local drug production and reducing import dependency.
-
Rising demand for biologics, biosimilars, and cell & gene therapies.
-
Increasing chronic disease burden in cardiology, oncology, neurology, and diabetes care.
-
Strong generic segment driving affordability and access.
-
Expansion of health insurance coverage improving patient drug accessibility.
Key Market Drivers
-
Government strategies such as the Vision 2023 Plan aimed at making Turkey a healthcare manufacturing hub.
-
Increase in chronic diseases: Growing demand for cardiovascular, oncology, and neurology medicines.
-
Growth of generics manufacturing reducing costs for consumers.
-
Rising investment in biologics and biosimilars, including monoclonal antibodies.
-
Healthcare digitization driving innovative treatment delivery and clinical trials.
-
International trade opportunities: Pharmaceutical exports to the Middle East, Africa, and Europe.
Market Segmentation
Breakup by Molecule Type
-
Biologics & Biosimilars (Large Molecules):
-
Monoclonal Antibodies – Strong demand in oncology and immunology.
-
Vaccines – Expanding production capacity for domestic and global supply.
-
Cell & Gene Therapy – Emerging segment with ongoing R&D initiatives.
-
Others – Hormones and recombinant proteins.
-
-
Conventional Drugs (Small Molecules):
-
Largest share at present, widely used for primary healthcare needs.
-
Breakup by Type
-
Branded Drugs: Dominant in specialty care areas such as oncology, vaccines, and neurology.
-
Generic Drugs: Fast-growing, supported by domestic manufacturers and cost-effective alternatives.
Breakup by Mode of Purchase
-
OTC (Over-the-Counter): Strong consumer demand for supplements, analgesics, and dermatology products.
-
Prescription-Based: Largest segment, especially for cardiology, immunology, and oncology treatments.
Breakup by Application
-
Cardiology: Leading application due to high prevalence of cardiovascular diseases.
-
Oncology: Rapid growth expected due to high R&D activity in cancer drugs.
-
Neurology: Significant share owing to rising cases of Alzheimer’s, Parkinson’s, and epilepsy.
-
Respiratory Diseases: Growing due to asthma, COPD, and infection treatment demand.
-
Immunology: Strong growth in monoclonal antibody and biologics adoption.
-
Dermatology: Increasing use of topical and biologic therapies for chronic skin conditions.
-
Others: Infectious diseases, rare diseases, and specialty care.
Breakup by Route of Administration
-
Oral: Most common route for small molecule drugs.
-
Topical: Popular in dermatology and pain relief.
-
Parenteral: Increasing use for biologics and specialty therapies.
-
Inhalations: Widely used for respiratory conditions.
-
Others: Includes nasal sprays and innovative delivery systems.
Breakup by End User
-
Hospitals and Clinics: Largest consumer segment due to chronic and acute care management.
-
Research and Academic Institutes: Strong focus on clinical trials and R&D.
-
Others: Retail chains and community-level care centers.
Breakup by Region
While the Turkey pharmaceutical market is a single nation analysis, its geographical positioning makes it a bridge between Europe and Asia, enabling cross-regional growth opportunities. Export demand is high from:
-
Europe (Germany, UK, and Eastern European countries).
-
Middle East & Africa (Saudi Arabia, UAE, and African markets).
-
Asia Pacific (Central Asia and Southeast Asia for generics and vaccines).
Competitive Landscape
The Turkey pharmaceutical market has a mix of strong domestic manufacturers and international multinationals. Recent trends show an emphasis on technology licensing, biosimilar partnerships, and manufacturing collaborations.
Key Companies Covered
-
Abdi İbrahim Pharmaceuticals (largest Turkish pharma manufacturer)
-
Deva Holding A
-
Sanofi
-
Novartis
-
Pfizer
-
Bayer
-
İlko Pharmaceuticals
-
Amgen
-
AstraZeneca
-
Koçak Farma
Company Insights
-
Abdi İbrahim & Deva Holding: Leading domestic players with strong generic portfolios and export reach.
-
Sanofi, Pfizer, Novartis, Bayer, AstraZeneca: Multinationals reinforcing biologics and specialty drugs.
-
Amgen & Koçak Farma: Leaders in biosimilars and specialty pharma collaborations.
-
İlko Pharma: Expanding innovative drug pipeline in niche therapies.
Emerging Trends in the Turkey Pharmaceutical Market
-
Rise of biosimilars and biologics in Turkey’s domestic market.
-
Integration of digital health platforms into patient management.
-
Government regulatory reforms improving affordability and access.
-
Growth of clinical research organizations enabling global trials within Turkey.
-
Export-oriented pharmaceutical growth positioning Turkey as a regional pharma hub.
-
Greater adoption of cell and gene therapies with future regulatory support.
Future Outlook
By 2034, the Turkey pharmaceutical market is projected to exceed USD 14.98 billion. Growth trends point toward:
-
Domestic expansion of biologics and biosimilars manufacturing.
-
Increased exports to Europe, the Middle East, and Africa.
-
Digital health integration for supply chain and clinical management.
-
Sustained government support through subsidies, incentives, and long-term health reforms.
-
Rising private sector involvement in drug discovery and clinical research.
Turkey has the potential to become a regional pharmaceutical hub, balancing affordability, innovation, and public health demands.
Browse More Reports
Healthcare Cloud Computing Market
Assisted Reproductive Technology Market
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
